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Abstract
The v-erbA oncogene coding for a mutated form of the
thyroid hormone (T,) receptor (TRaI) increased the
invasion capacity of the mouse B3.1 glial cell line. This
effect was mediated by the induction of platelet-
derived growth factor (c-sis/PDGF B), as shown by its
inhibition using an anti-PDGF BB antibody. Also, the
low invasion capacity of parental B3.1 and c-erbA-
expressing cells (B3.1 + TRaI) was enhanced by
exogenously added PDGF BB. This effect was
independent of the growth-promoting activity of PDGF
and unrelated to the secretion of metalloproteinases.
All three cell types (parental B3.1, B3.1 + v-erbA, and
B3.1 + TRaI) secreted similar high levels of the Mr
72,000 collagenase IV (A) independently of PDGF.
Mchorage-independent cell growth was also
enhanced by v-ethA B3.1 + v-ethA cells but neither
parental B3.1 nor B3.1 + TRaI cells formed foci in soft
agar. The effect of v-erbA only happened in the
presence of serum, suggesting that some serum
factor(s) cooperate with PDGF to overcome the
anchorage dependence of B3.1 + v-erbA cells.
Supporting this, high doses of exogenous PDGF were
much less efficient than serum, and the addition of an
anti-PDGF BB antibody blocked only partially the effect
of serum. Basic fibroblast growth factor was found to
cooperate with PDGF to abolish anchorage
dependence. Moreover, B3.1 + v-erbA cells detached
and grew in suspension when cultured on plastic
dishes. Interestingly, the transformation-competent
c-jun and fra-1 oncogenes were induced by v-erbA in
serum-free medium and are candidates to mediate
v-erbA effects. In summary, our results show that v-
erbA induces transformation parameters in the glial
B3.1 cell line via an increase in c-sis/PDGF B and
probably other mechanisms, suggesting a role for
(autocrine) PDGF stimulation in glial cell
transformation.
Introduction
The v-erbA oncogene is present in the genome of the avian
erythroblastosis virus, a retrovirus causing rapid, fatal eryth-
roleukemia and also sarcomas in chickens (reviewed in Ref.
1). v-erbA does not cause tumors by itself but potentiates the
tumorigenic capacity of v-erbB, the second oncogene in
avian erythroblastosis virus encoding a truncated epidermal
growth factor receptor (2, 3). By blocking the cell differenti-
ation program and decreasing the requirements for growth
factors and conditions, v-erbA enhances erythroblast trans-
formation by v-erbB (3, 4), endogenous c-erbB (5), several
other tyrosine-kinase (v-src, v-fps, and v-sea; Ref. 6), the
signal-transducer v-Ha-ras (6), and the nuclear v-ets (7) on-
cogenes. In culture, v-erbA does not transform chicken bone
marrow cells or fibroblasts (3). However, it does causes an
outgrowth of erythrocytic cells (8) and stimulates fibroblast
growth and in vivo tumorigenesis of v-erbB-transformed fi-
broblasts (9).
v-erbA is a mutated version of the thyroid hormone (Ta)
receptor ai (TR/c-erbAai ; Refs. 10 and 1 1), a member of the
family of nuclear hormone receptors that function as se-
quence-specific, DNA-binding, ligand-activated transcnp-
tion factors (1 2, 13). Due to several mutations, v-erbA is
unable to bind hormone (1 0, 14) but still binds DNA, albeit
with an altered affinity (15-1 7). Additional mutations in the
carboxy-terminal domain of v-erbA have also destroyed the
heterodimerization, gene silencing, and hormone-dependent
transactivation capacities present in the normal TR!c-erbAai
receptor (1 8-20). As a result, v-erbA interferes with the nor-
mal transcriptional transactivating activity of TRa1 and per-
haps other nuclear receptors, such as RAR.3 Thus, v-erbA is
considered a constitutive, dominant transcriptional repressor
of hormone-activated specific genes (1 5, 21-23). In line with
3 The abbreviations used are: RAR, retinoic acid receptor; PDGF, platelet-
derived growth factor; bFGF, basic fibroblast growth factor; TGF, trans-
formIng growth factor.
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this, the arrest by v-erbA of chicken erythroblast differentia-
tion induced by activated TR!c-erbA and RAR is at least in
part a consequence of the transcriptional inhibition of three
genes: carbonic anhydrase II, band 3, and &.aminolevulinic
acid synthethase (4, 18, 24).
In agreement with the broad expression of TR!c-erbA in
the organism, v-erbA also has effects on the phenotype of
other cell types. In rat pheochromocytoma PC12 cells, it
causes a partial blockade of the neuronal differentiation in-
duced by nerve growth factor and a potentiation of the
dexamethasone-induced chromaffin differentiation and gene
expression (25). Strikingly, v-erbA increases quail myoblast
proliferation and terminal differentiation without affecting TR!
c-erbA action (26). On the other hand, v-erbA cooperates
with bFGF in neuroretina cell transformation (27). Recently,
v-erbA has been shown to induce multiple alterations, in-
cluding loss of adipose tissue and hepatocellular carcino-
mas, in transgenic mice (28). This result shows that in vivo
v-erbA transforms hepatocytes, which histologically are ep-
ithelial cells. Consequently, v-erbA blocks brown adipose
cell differentiation and gene expression in vitro.4
To study its effects in glial cells, we have expressed v-erbA
and, in parallel, its cellular counterpart, the chicken TRIc-
erbAai , in an immortal mouse glial cell line named B3.i (29).
We reported the inhibition by v-erbA of the expression of
CNP, an oligodendrocytic marker gene, together with an
increase in DNA synthesis and changes in the response to
growth factors (29). More recently, we characterized the
increase in cell survival and proliferation caused by v-erbA as
the consequence of the induction and secretion of PDGF,
and the autocrine response of v-erbA-expressing cells (B3.i
+ v-erbA)(30). Given that both types of glial cells, astrocytes,
and oligodendrocytes express TR/c-erbA in vivo and are the
target of T3 action (Refs. 29 and 31 , and references therein),
and the important role attributed to PDGF in the process of
malignization of different cell types including glial cells (32-
35), we have analyzed the phenotype of B3.i + v-erbA cells.
Here we report the effects of v-erbA on two transformation
parameters, invasive capacity and anchorage-independent
growth, and their relation to the induction of PDGF. In addi-
tion, the study of gene expression in B3.i + v-erbA cells
revealed that at least two other genes with oncogenic po-
tential, c-jun and fra-i , are induced by v-erbA in these cells.
Results
v-erbA Increases Cell Invasiveness. To investigate
whether the induction of PDGF B by v-erbA could cause
phenotypic changes related to transformation in addition to
the observed growth potentiation, we first analyzed the in-
vasive capacity of B3.i + v-erbA cells. As shown in Fig. 1 ,a
clear difference was found among the different cell types.
B3.i + v-erbA cells exhibited a much higher capacity to
invade a natural matrix (Matrigel) than the parental B3.i or
the B3.i + TRai cells, and which is comparable to that of the
highly malignant Bi6FiO murine melanoma cells used as
positive control. The same result was obtained when GFR-
Matrigel, containing reduced amounts of several growth fac-
tors (epidermal growth factor, PDGF, insulin-like growth fac-
tor-l) and proteases or collagen type I were used instead of
normal Matrigel (data not shown).
To evaluate the role of PDGF in the increase in cell inva-
siveness, the effect of a neutralizing anti-PDGF BB antibody
was tested. The addition of anti-PDGF BB to the B3.i +
v-erbA cells when they were seeded on the Matrigel reduced
substantially (around 4-fold in three independent experi-
ments) the amount of cells that invaded the matrix (Fig. 14).
The specificity was assessed by using an antibody directed
against bFGF that was much less inhibitory, and a control
antibody against the nuclear growth hormone factor-i had
no effect. The importance of PDGF in B3.i + v-erbA inva-
siveness was further confirmed by treatment of cells with
exogenous PDGF. Thus, the addition of 10 ng/ml PDGF BB
led to a high increase in the invasiveness of parental B3.i
cells (Fig. 2B, E) and a less pronounced increase in the case
of B3.i + TRai cells (Fig. 2B, 0). No effect of this treatment
could be observed at the time of analysis (4 days after
seeding) on B3.i + v-erbA cells, which had mostly crossed
the matrix in untreated cultures (Fig. 2B, S).
Next, we investigated the possibility that the observed
effect of PDGF could be a simple consequence of its growth-
promoting activity. To test this, increasing amounts of cells
were used in the invasion assay. Fig. 3A shows that the
increase in B3.i + TRai cell density (0) to even nearly
confluency (up to 9 x 1O cells/Transwell) had no major
effect on their reduced invasiveness. In the case of B3.i +
v-erbA cells (Fig. 3A, U), very high cell densities resulted in a
decreased number of cells attached to the porous mem-
brane underlying the matrix; but this is due to the fact that
they had even crossed the membrane and could be recov-
ered from the lower chamber of the well. In another series of
experiments, the growth-promoting activity of PDGF was
abolished by treating the cells with mitomycin C, a drug
which inhibits cell division. Supporting a growth-indepen-
dent effect of PDGF, mitomycin C-treated B3.i + v-erbA
cells showed a higher invasion capacity than B3.i + TRai
cells (data not shown).
The effect of serum was then examined. Increasing
amounts of serum greatly augmented the invasion capacity
of B3.i + TRai cells (Fig. 3B, 0). In contrast, the invasive-
ness of B3.i + v-erbA cells was not augmented by low
(0.5%) serum concentrations and was doubled by higher
(2-4%) concentrations (Fig. 3B, ). Comparing both cell
types, we observed that the difference in the invasive poten-
tial is lost at low serum and is evident again at 2-4% serum.
No differences were seen at 10% serum. Together with data
obtained using PDGF treatments (Fig. 2B), these results
suggest that PDGF is a major factor responsible for the
higher invasion capacity of B3.1 + v-erbA cells but also that
other uncharacterized serum factors, either alone or in co-
operation with PDGF, enhance the invasiveness of these
cells. These factors are probably responsible for the increase
in B3.i + TRai cell invasiveness observed at 0.5% serum.
However, their concentration at this low serum condition
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Fig. 2. Effects of PDGF on the invasive potential of B3.i cells. A, inhibition of B3.i + v-erbA cell invasiveness by an anti-PDGF BB antibody. Three x i O
B3.1 + v-erbA cells were incubated on Matngel as in legend for Fig. 1 in the absence or presence of antibodies against PDGF BB, GHF-i , or bFGF as
indicated. Antibodies were added to the cells at the time of seeding (day 0) and 48 h later (day 2). Photos of hematoxylin and eosin-stained inserts were
taken 4 days after seeding. B, effect of exogenously added PDGF on cell invasiveness. Quantitation of invasive cells in cultures of parental B3.i cells 1),
B3.i + TRai (LI), and B3.i + v-erbA () cells treated or not with 10 rig/mI PDGF BB at days 0 and 2. In both cases, two separate experiments were done,
giving the same result.
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Fig. 1. Invasion capacities of parental B3.i , B3.i
+ TRai , and B3.i + v-erbA cells. Cells (3 x 1O/
6.5-mm Transwell insert) were seeded on Matrigel
in serum-free medium as described in “Materials
and Methods” and incubated for 4 days at 37CC.
Fibronectin was used as chemoattractant, and met-
astatic Bi 6Fi 0 cells were used as controls. A, pho-
tos of the Transwell inserts after Giemsa staining. B,
spectrophotometric quantitation of cells attached
to the insert by incubation with culture medium
containing 6.25 pg/mI 2’,7’-bis-(2-carboxyethyl)-5-
(and -6)-carboxyfluorescein-acetoxymethyl ester
for 1 0 mm at 37”C. C, micrographs of the Transwell
inserts. The attached, stained invasive cells and the
clear insert pores are visible. Four separate exper-
iments were done, giving the same results.
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Fig. 4. Collagenase secretion by the three B3.i cell types. Gelatin zy-
mography of conditioned media (CM) from parental B3.1, B3.1 + TRai,
and B3.i + v-erbA cells. Gelatin-SDS-polyacrylamide substrate gels were
used to visualize the gelatinolytic activity in the CM of the respective cell
types treated or not with the indicated growth factor (10 ng/ml; 2 days) as
described in “Materials and Methods.” Purified type Xl collagenase was
added to Lane C as a positive control. Right, the size of the active protein
(Mr 72,000).
and invasiveness but in contrast to its action on other cell
types (Ref. 36 references therein), it does not induce a che-
motactic response in these cells.
v-erbA Does Not Affect Proteolytic Activity. Since in-
vasiveness is the result of the capacity of cells to attach,
digest, penetrate, and cross the surrounding extracellular
matrix, we examined whether B3.i + v-erbA cells exhibited
a higher secretion of metalloproteinases, a major group of
enzymes degrading multiple matrix components. We used
gelatin zymography to analyze the secretion of collagenases
by the different cell types. The effect of several growth fac-
tors was also studied. As shown in Fig. 4, the three cell types
secreted basically only high amounts of a gelatinase of Mr
72,000, which most probably corresponds to collagenase IV
A or MMP-2. No differences were found among the parental
B3.1 , B3.1 + TRa1 , and B3.1 + v-erbA cells. Furthermore,
the high secretion of this collagenase was not affected by
exogenous PDGF BB, TGF-a, or bFGF in any cell type (Fig.
L
SERUM (%)
Fig. 3. Effect of cell density and serum concentration on the invasion
capacities of B3.i + TRai and B3.1 + v-erbA cells. A, the indicated
number of cells were seeded on Matngel as in legend for Fig. 1 . Four days
later, invasive cells were stained with crystal violet and quantitated as
described in “Materials and Methods.” B, 3 x iO cells (El, B3.1 + TRo1;
., B3.i + v-ethA) were seeded in the presence of the indicated serum
concentrations. Quantitation of invasive cells was as in A. In both cases,
two experiments were done, giving the same result.
does not appear to be enough to potentiate the effect of
PDGF.
On the other hand, we also studied the effect of PDGF as
a chemoattractant. The presence or absence of PDGF (or the
commonly used chemoattractant fibronectin) in the lower
chamber did not change the respective invasive capacities
on Matrigel or collagen type I gels described above (data not
shown). Therefore, PDGF BB increases B3.1 cell proliferation
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Fig. 6. Anchorage-independent growth of B3.1 + v-erbA cells. The three
B3.1 cell types were analyzed for anchorage-independent growth in soft
agar as described in “Materials and Methods.” Representative foci were
photographed 6 weeks after seeding. Bar, 1 00 m.
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Fig. 5. Growth of B3.i + v-erbA cells in suspension. Phase micrographs
of arrays of floating B3.1 + v-erbA cells growing on top of cell monolayers
4 days after seeding. A: bar, i 00 m. B: bar, 50 jm. Arrows, cells in
mitosis.
4). In addition, low and again unchanged secretion of another
gelatinase of Mr 97,000 (probably collagenase IV B or
MMP-9) was found when 1 0-fold concentrated conditioned
media were used (data not shown). On the other hand, none
of the cell types treated or not showed detectable secretion
of proteases of the stromelysin family, as assessed by casein
zymography (data not shown).
v-erbA Induces Anchorage-independent Proliferation.
We noticed that a percentage of B3.i + v-erbA cells invari-
antly detached from the plastic dishes during standard cul-
turing. An increasing number of cells formed groups floating
in the medium on top of the monolayer on the days following
seeding in a dish (Fig. 5). This phenomenon was not a con-
sequence of high cell density since it started well before
monolayers reached confluency. Floating cells tended to
contact; therefore, many arrays of cells showing a flat mor-
phology could be seen after 3-4 days. Furthermore, cells in
suspension were able to divide, as assessed by the mitosis
seen regularly (Fig. 5, arrows in lower panel).
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The ability to grow in the absence of anchorage to solid
substrate is another characteristic of transformed cells. We
next investigated the capacity of the different cell types to
form foci in semisolid agar, a typical test of cell transforma-
tion. In the presence of high (i 0%) serum, a clear difference
was seen; B3.1 + v-erbA cells (270 foci counted in 6 fields)
but not parental B3.i (6 foci in 6 fields) or B3.i + TRa1 cells
(2 foci in 6 fields) formed multicellular foci after a few (4-6)
weeks (Fig. 6). A high percentage of B3.i + v-erbA cells were
present in big multicellular foci of either well-limited, encap-
sulated-Iike (Fig. 6, upperleft panel) or more irregular (Fig. 6,
upper right panel) shape, and the remaining cells formed
small groups. Both parental B3.1 and B3.1 + TRcrl cells
remained exclusively as individual cells. However, the result
was different when the cells were seeded in the absence of
serum. Then, B3.1 + v-erbA cells were, as the parental and
B3.1 + TRa1 cells, equally unable to form foci. Assuming
that v-erbA is able to induce PDGF when the cells are cul-
tured in semisolid agar, this result suggested that PDGF is
not sufficient to induce foci formation but probably requires
the cooperation with other serum factor(s). To confirm this,
two types of experiments were done: (a) we used an anti-
PDGF BB antibody to study the contribution of the v-erbA-
induced PDGF to the formation of foci by the B3.1 + v-erbA
cells. Only a partial (50%) inhibition of foci number was
obtained, which indicated that other factor(s) must cooperate
with PDGF (Fig. 7). A candidate was bFGF, which cooperates
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Fig. 7. Effect of an anti-PDGF BB antibody on the anchorage-independent growth of B3.1 + v-erbA cells. Cells were seeded in 24-well plates in the
presence of serum or the indicated factors (1 0 ng/mI) alone or plus 1 0 g/ml anti-PDGF BB antibody as described in “Materials and Methods.” Foci present
in six nonoverlapping fields were photographed and counted 2 weeks after seeding. Three experiments were done. Mean values correspond to one
representative experiment. U, no antibody added; , anti-PDGF BB antibody; El, control anti-GHF-i antibody. Bar, 1 00 jim.
with PDGF regulating growth and differentiation of glial 02A
precursors; and (b) we analyzed foci formation by the B3.1 +
v-erbA and B3.i + TRal cells cultured in the presence of
serum, PDGF BB, or bFGF. Although high doses of PDGF
were only able to induce the formation of small groups of
B3.1 + v-erbA cells, bFGF was basically as efficient as
serum in inducing foci, which showed an irregular and less
compact morphology (Fig. 8). Cell clones formed by PDGF-
treated B3.1 + TRa1 cells were very small, whereas no
differences were seen between bFGF-treated B3.l + v-erbA
and B3.1 + TRa1 cells (Fig. 8, lowerpanels). In line with this,
the anti-PDGF BB antibody caused a 50% reduction in the
number (and also some reduction in the size) of foci formed
by B3.1 + v-erbA cells treated with bFGF + PDGF (Fig. 7). As
expected, the anti-PDGF BB antibody abolished completely
the effect of exogenous PDGF (data not shown).
Effects of v-erbA on Gene Expression: Induction of
c-jun and fra-1. To gain insight on the basis for the de-
scribed effects of v-erbA, we initiated a broad study of gene
expression in B3.1 + v-erbA cells. Around 40 genes encod-
ing proteins involved in processes more or less closely re-
lated to cell transformation or proliferation were analyzed (in
addition to PDGF A and B and their receptors; Ref. 30).
Northern blots containing mRNAs prepared from the three
cell types growing in either complete, serum-containing
growth medium, or in N2 serum-free medium (see “Materials
and Methods”) and specific cDNAs probes were used in this
screening. Results obtained are summarized in Table 1.
Three types of genes were found: (a) genes whose expres-
sion at the mRNA level were altered in B3.1 + v-erbA cells;
(b) genes whose mRNA levels were unaffected by v-erbA
(and also by TR/c-erbAc1); and (c) genes that were not
expressed in B3.1 cells. In the first and obviously most in-
teresting group are two nuclear oncogenes: c-jun and fra-1.
In both cases, the cellular content of their respective mRNAs
(2.7 and 3.0 kb for c-jun; 1 .6 kb for fra-1) was much higher in
B3.i + v-erbA cells than in parental B3.1 or B3.1 + TRa1
cells in serum-free conditions (Fig. 9). No big differences
were seen in the presence of serum. In none of the other
genes studied, including those encoding other nuclear and
non-nuclear oncogenes, growth factors, and growth factor
receptors, matrix proteins, membrane and nuclear receptors,
and proteases and proteases inhibitors, were significant dif-
ferences found (Table 1).
Discussion
In this study, we report the effects of the v-erbA oncogene on
the phenotype of the B3.1 glial cell line. We have shown
previously that v-erbA induced the expression and secretion
of active PDGF in these cells, which were in turn stimulated
to proliferate in an autocrine fashion (30). Analogous auto-
crine growth stimulations by PDGF have been described in
other systems, including glioma cells (Refs. 37 and 38 and
references therein). More importantly, autocrine PDGF stim-
ulation induces transformation of NIH 3T3 fibroblasts (39-
41). Also, the growth and in vivo tumorigenicity of glioma cell
lines parallels their PDGF secretion (32, 34), and the exis-
tence of a PDGF autocrine loop in gliomas appears to cor-
relate with tumor progression (35).
Here we show that v-erbA induces two transformation
parameters in B3.1 cells: invasiveness of a complex, natural
extracellular matrix; and anchorage-independent growth.
These two biological effects are related, but perhaps dis-
tinctly, to the induction of PDGF B. Cell invasiveness induced
by v-erbA is mediated to a great extent by PDGF since
suppression of PDGF activity by a specific anti-PDGF BB
antibody mostly abrogates this effect. The results obtained
by treating the cells with exogenous PDGF or serum suggest
that the v-erbA-induced production of PDGF is responsible
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Fig. 8. Effect of exogenous PDGF and bFGF on foci formation by B3.i +
v-erbA and B3.i + TRoi cells. Cells were seeded in 24-well plates and
treated with the indicated factors (10 ng/ml) as described in “Materials and
Methods.” Three experiments were done, giving the same results. Photos
of representative foci are shown. Bar, 1 00 j.m.
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for a nearly maximum stimulation of cell invasiveness. How-
ever, it seems that other serum factor(s) in addition to PDGF
is able to increase the invasive potential of B3.1 cells. Still,
the differences observed could be a mere consequence of
the (PDGF-induced) more active state of the B3.l + v-erbA
cells than the parental or the B3.1 + TRa1 cells. Against this
possibility, replication-arrested B3.1 + v-erbA cells by mit-
omycin C treatment showed higher invasiveness than B3.i +
TRai cells. On the other hand, our data demonstrate that the
anchorage-independent growth of B3.i + v-erbA cells is the
result of the cooperation between the PDGF BB produced by
the cells and a serum factor(s) that may very well be bFGF.
v-erbA induces proliferation of chicken erythroblasts and
fibroblasts by not yet well-characterized mechanisms, which
may include the abrogation of the inactivation of the AP-1
(jun/fos) transcription factor by normal nuclear hormone re-
ceptors (42, 43). In this respect, the induction of higher levels
of c-jun and fra-1 mRNAs might play a role in the phenotypic
changes observed in B3.1 + v-erbA cells. Both are transfor-
mation competent oncogenes, the oncogenic potential of
which can be achieved by overexpression (44, 45). In fact,
fra-1 abrogates anchorage-dependent growth and induce in
vivo tumorigenicity of rat fibroblasts (45). Therefore, although
a definitive comprobation is required, c-jun and fra-i are
potential candidates to mediate at least part of the trans-
forming activity of v-erbA in these cells.
On the other hand, v-erbA has been reported to augment
the proliferative response to epidermal growth factor (46) and
block RBC apoptosis by unregulated thyroid hormone re-
ceptor/RAR (47). Also, the expression the oncogenicity of
v-erbA has been shown to require phosphorylation (48) and
the cooperation with tyrosine kinase oncogenes (reviewed in
Refs. 24 and 49). It is plausible, then, that the activation of
PDGF-signaling pathways in B3.1 + v-erbA cells can con-
tribute to transform these cells by cooperating with other
mechanisms triggered by v-erbA. A similar reasoning would
also explain the increase in v-erbA transforming effects seen
in the presence of serum.
We have not found effects of v-erbA on the secreted
proteolytic activity of B3.1 cells. If true, this would mean that
the increase in invasiveness induced by v-erbA is exerted by
enhancing cell motility and/or the dynamic interactions with
the extracellular matrix, which are additional necessary re-
quirements for cell invasion. However, changes in the activity
of metalloproteinases or the involvement of other types of
proteases undetectable by the current zymography assays
cannot be totally ruled out.
An additional biological effect of PDGF is the induction of
chemotaxis in several cell types (Refs. 36 and references
therein). However, we have not found any chemotactic ac-
tivity of exogenous PDGF on B3.1 cells. One possible expla-
nation is the PDGF autocrine stimulation of B3.1 + v-erbA
cells. Thus, it has been reported that an excess of early
signaling inhibits the chemotactic response to PDGF of NIH
3T3 cells (50). Alternatively, the lack of chemotaxis of B3.1
cells may represent a cell-specific response.
It is also worth noting that B3.1 cells were originally es-
tablished by infection of primary mouse brain cell cultures
with a v-myc-expressing retrovirus. Therefore, the three B3.i
cell types express v-myc, as checked in Northern blots (29).
The possibility exists, then, that part of the results here
shown could be due to the cooperation between v-erbA and
v-myc oncogenes.
In summary, our results indicate that v-erbA has trans-
forming activity of the B3.i glial cells through mechanisms
involving an autocrine PDGF stimulation, and perhaps the
induction of other nuclear oncogenes such as c-jun and
fra-1 . These data support a role for the normal thyroid hor-
mone receptor/c-erbA and its ligand T3 in the maintenance of
the differentiated phenotype of glial cells, and the interest of
the analysis of the integrity and expression of erbA genes in
glioma tumors.
Materials and Methods
B3.i Cell Culture. Cells were grown in Ham’s Fi2 medium supple-
mented with 10% FCS, 2 m glutamine (all from GIBCO), and 20 mri
+ + +
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Table 1 Gene expression in parental B3.1 , B3.1 + TRo1 and B3.1 + v-erbA cells
Cells were grown in either complete growth medium or serum-free medium (see “Materials and Methods”). PoIy(A) RNA were prepared and analyzed
in Northern blots as described in “Materials and Methods” and hybrized to specific cDNA probes. Cyclophilin was used as control gene.
Increased in B3.1 + -Unaffected by v-erbA or TRo1 Undetectable expression
v-erbA cells
c-jun junB, junD, c-fos, fosB, TGF-a, TGF-31 , -32 and -33, RCC1, butyrophilin, fra-2, a2/a3 integrins, entactin,
fm-i TIMP-1 and -2, CD44, MEP, f31-integrin, fibronectin, hepatocyte growth factor, c-met, Sloop, SGP-2, PAl-i
NURR1 , NGF1 B, collagen type I, glutamine synthetase, and -2, N-CAM, carbonic anhydrase II, stromelysin-i
EGF-R, c-erbB2/neu, 3i laminin and -2
FCS
c-jun
fra-1
Cy
B3.1+ B3.1+
B3.1 TRa1 v-erbA
Fig. 9. Expression of c-jun and fra-1 in parental B3.i , B3.i + TRo1 , and
B3.1 + v-erbA cells. Cells were incubated in medium containing (+) or not
(-) FCS for 2 days. Poly(A) mRNA was then purified, and 10 ig were
analyzed in Northern blots as described in “Materials and Methods.”
Cyclophilin (Cy) was used as control. Two separated experiments were
done, giving the same result.
glucose. For serum-free medium, we used the N2 medium described by
Bottenstein and Sato (51) with the following composition: DMEM and
Ham’s F12 media (both from G1BCO) at a 1:1 ratio supplemented with 15
g/ml insulin, 100 pg/mI transferrmn, 20 flM progesterone, 30 flM sodium
selenite, 1 00 jtM putrescine, 2 mM glutarnine (GIBCO), 0.03% BSA, and 15
mM HEPES (pH 7.3; unless specified, all from Sigma).
Growth Factors and Antibodies. Human recombinant PDGF BB was
purchased from Boehringer Mannheim, and human recombinant bFGF
was a generous gift from Farmitalia Carlo Erba. Rabbit polyclonal antihu-
man PDGF BB antibody was obtained from Genzyrne, the monoclonal
anti-bovine bFGF was from Upstate Biotechnology, Inc. and the rabbit
polyclonal antirat GHF-i was a gift from Dr. M. Karin (University of Cali-
fornia-San Diego, La Jolla, CA).
Invasion Assays. Cell invasion capacity was evaluated using a mod-
ified Boyden chamber assay (52). Polyvinylpyrrolidone-free polycarbonate
filter Transwell inserts (6.5-mm diameter) with 8.0 jm pores (Costar) were
used. Inserts were set in 24-well culture plates (Falcon) and incubated
overnight at 37”C with 0.1 mg/mI gelatin in 0.1 % acetic acid/PBS solution
and dried for 5 h. Matrigel, GFR-Matrigel, or collagen type I (Collaborative
Research) were applied (4 g in 50 pJ cold PBS) to the upper surface of
each filter and were dried at room temperature under a UV lamp inside a
hood. When indicated, human fibronectin (5 .tg in 500 l culture medium)
or PDGF BB (1 0 nglml) were added to the lower chamber as chemoat-
tractants. Cells (3 x 1 o, unless specified) were seeded in serum-free
medium (unless indicated) in the upper chamber in 200 d medium. The
highly metastatic murine melanoma B16F1O cells (53) were used as pos-
itive control. After incubation for 4 days, cells on the upper side and matrix
were removed with cotton swabs. For visualization, inserts were stained
with hematoxylin and eosin, cut out with a scalpel, and photographed with
a Nikon FX-35 camera under an inverted IMT Olympus microscope. For
quantitation of invasive cells, Transwell inserts (where attached) were
incubated for 1 0 mm at 37”C with culture medium containing 6.25 .tg/mI
2’,7’-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein, acetoxymethyl
ester for 1 0 mm at 37#{176}C.When visualization was not required, cells were
fixed with 1 % glutaraldehyde for 10 mm, washed twice with PBS, and
stained with 0.1 % crystal violet for 30 mm. After three washes with
deionized water, the cell-attached dye was dissolved in 1 0% acetic acid
and measured at A595.
Proteolytic ACtiVity Assays. To estimate the secretion of extracellular
matrix degradation enzymes by the different cell types, gelatin and casein
zymograms were performed as described (54). Volumes of serum-free
conditioned media normalized to protein content were electrophoresed
on 10% SDS-polyacrylamide gels containing gelatin (1 mg/mI) from bo-
vine skin (Sigma) or 3-casein (0.5 mg/mI) from bovine milk (Sigma). Con-
ditioned media were prepared from cells seeded in 60-mm dishes, which
were washed twice with PBS and switched to 3 ml N2 medium for 48 h.
Media were collected and spun down for 5 mm in a refrigerated Sorvall
centrifuge at 2500 rpm to remove cell debris. Centriprep-3 (Amicon)
columns were used for 1 0-fold concentration when required. Purified type
Xl collagenase from Clostridium histolyticum (Sigma; 1 pg/mI) was loaded
as positive control in the gelatin gels. After electrophoresis, the gels were
rinsed twice in 2.5% Triton X-100/50 mpi Tris (pH 7.4)for 30 mm and twice
in 50 mM Tns (pH 7.4) for 10 mm to remove the SDS and then incubated
for 22 h at 37#{176}Cin substrate buffer [50 mi Tris-HCI buffer (pH 7.5), 10 m
CaCI2, 150 mri NaCI, 0.1 % Triton X-100, and 0.02% NaN]. The gels were
stained for 1 h in 30% methanoVl0% glacial acetic acid containing 0.5%
Coomassie Brilliant Blue and destained in the same solution in the ab-
sence of dye.
Soft Agar Foci Formation Assays. Ten thousand cells were sus-
pended in 2 ml 0.35% Difco Noble agar in DMEM containing 10% FCS
over a basal layer of 0.5% agar (3 ml). Two and 4 weeks later, the cells
were refed by overlaying 2 ml of 0.35% agar in the same medium, and
colonies were photographed 6 weeks after seeding. For the tests of
activity of PDGF, bFGF, and the anti-PDGF BB antibody, we seeded the
same number of cells in 250 .d 0.35% Difco Noble agar containing or not
the indicated factor (1 0 ng/ml) or antibody (1 0 g/ml) over a basal layer of
0.5% agar (300 s.d) in 24-well plates. Cells were fed every 2 days with 100
.d N2 medium containing the corresponding factor or antibody. In these
experiments, foci appeared earlier (1 0-14 days).
RNA Preparation and Northern Analysis. Purification of poly(A)
RNA from cells was done as described (55). Northern blots were per-
formed on nylon membranes (Nytran; Schleicher and Schuell) according
to standard protocols (56). All probes were labeled by the random priming
method (57). Hybridizations were carried out overnight at 65”C in 7%
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SDS/500 mM sodium phosphate buffer (pH 7.2) and 1 m EDTA, accord-
ing to Church and Gilbert (58). Filters were washed twice for 30 mm each
in 1 % SDS and 40 mM sodium phosphate buffer (pH 7.2) at 65#{176}C.Before
rehybndizing the nylon membranes with probes for other genes, the
radioactive probe was stripped off the membrane by placing it in a 75#{176}C
water bath for 5 mm. Membranes were exposed to Kodak X-Omat AR
films.
Probes. Probes used in this study were provided by Dr. Rodrigo Bravo
(c-fun, junB, funD, c-fos, fosB, fra-2, fibronectin, and f31-mntegrin), Dr. M.
Busslinger (fra-1, MEP, PAl-i, and PAI-2), Dr. D. C. Lee (TGF-a), Drs. S.
w. Qian and A. B. Roberts (TGF-f31 , TGF-2, and TGF-3), Dr. E. Wagner
(liMP-i), Dr. D. A. Edwards (T1MP-2), Dr. U. G#{252}nthert(CD44), Drs. R. M.
Evans and T. Perlmann (NURR1 and NGF1-B), Dr. V. Yamada (1-laminin),
Dr. C. Birchmeler (hepatocyte growth factor), Dr. A. E. Chung (entactin),
Dr. M. E. Hemler (a2/a3 integrins), Dr. J. Newport (RCC1), Dr. S. R.
Sylvester (SGP-2), Dr. I. H. Mather (butyrophilin), Dr. G. F. Vande Woude
(c-met), Dr. A. Marks (S100j3), Dr. Z. Q. Wang (collagen type I), Dr. R. E.
Breathnach (stromelysin 1), Dr. L M. Matrisian (stromelysin 2), Dr. C.
Goridis (N-CAM), Dr. W. H. Lamers (glutamine synthethase), and Dr. P. J.
Curtis (carbonic anhydrase lI).
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